PRFX - רווח נקי למניה (EPS TTM) PainReform Ltd

PainReform Ltd. delegates production and testing to external contractors, creating a strong dependency on vendors. Net income per share over the last four quarters helps identify the real business trend, where the value of -5.27 shows the most recent figure. Investors are awaiting approval of the PRF-110 gel, relying on FDA support. The company's goal is to replace opioids with safe methods of prolonged pain relief.

This metric is calculated as the ratio of total annual net income to the number of shares outstanding. The metric determines the actual earnings per share, neutralizing the impact of issuance. For PainReform Ltd. (PRFX), this calculation is critical when competing with behemoths in the hospital segment. Profit growth confirms the effectiveness of niche analgesic drugs. By analyzing the company's EPS TTM dynamics, an investor assesses the fundamental resilience of the business to market pressure.